Canntab Therapeutics Limited announced earnings results for the third quarter ended February 28, 2021. For the third quarter, the company announced total revenue was CAD 465,375. Net loss was CAD 604,697 compared to CAD 670,904 a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.03 a year ago. For the nine months, total revenue was CAD 843,375 compared to CAD 133,334 a year ago. Net loss was CAD 2.115 million compared to CAD 1.733 million a year ago. Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.07 a year ago.